PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD)

PYC已经为全世界500万患有多囊性肾病变的人开发了一种新的候选药物

This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2]

这种候选药物已经在来自PKD终末期肾衰竭患者肾脏的人体模型中证明了有效性[2]

PKD is a life-changing disease affecting 1 in every 1,000 people[3]

PKD是一种改变生命的疾病，每1000人中就有1人患病

Half of the patient population with PKD will require a kidney transplant by the age of 60 due to the absence of impactful treatment options in this disease[4]

一半的PKD患者在60岁之前需要进行肾移植，因为这种疾病缺乏有效的治疗选择[4]

PKD represents an addressable market of >US$10 billion p.a. and is an area of major commercial interest for the drug development industry[5]

PKD代表了一个可寻址的市场，价值超过100亿美元，是药物开发行业的主要商业利益领域[5]

Pre-clinical models suggest that addressing the underlying cause of PKD (the way that PYC's drug candidate works) could arrest the course of the disease in humans, enabling damaged kidneys to regenerate and restore function[6]

临床前模型表明，解决PKD的根本原因（PYC候选药物的工作方式）可以阻止人类的疾病进程，使受损的肾脏再生和恢复功能[6]

PYC plans to accelerate this drug candidate into human trials in ~12 months – pursuing a potential high-velocity path through clinical trials to market[7]

PYC计划在大约12个月内将这种候选药物加速进入人体试验——通过临床试验走向市场的潜在高速路径[7]

Investor Webinar Friday 17 November

投资者网络研讨会11月17日星期五

PYC will host an investor call at 9am AWST/12pm AEDST on Friday 17 November to discuss these results – investors can register for the call here:

PYC将于11月17日星期五上午9点/下午12点召开投资者电话会议，讨论这些结果-投资者可以在这里注册电话：

https://us02web.zoom.us/webinar/register/WN_p2QQKKZ-TxOms2MOaUjijg PERTH, Australia and SAN FRANCISCO, Nov. 13, 2023 /PRNewswire/ -- PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD).

https://us02web.zoom.us/webinar/register/WN_p2QQKKZ-TxOms2MOaUjijg珀斯，澳大利亚和旧金山，2023年11月13日/PRNewswire/-PYC Therapeutics今天宣布一项研究结果，该研究是在人类三维模型中进行的，该模型源自常染色体显性多囊肾病终末期肾功能衰竭患者（PKD）。

The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8]..

结果表明，由PYC（称为PYC-003）设计的用于解决该疾病的根本原因的研究候选药物是有效的。这些3D患者衍生的囊肿模型代表了用于评估该适应症中候选药物的“金标准”临床前试验[8]。。

Continue Reading

继续阅读

Figure 1

图1

Figure 2

图2

Figure 3

图3

Figure 4

图4